Colony-stimulating factor use in the context of refined risk and benefit assessments.
Crawford
Jeffrey
J
Division of Medical Oncology, Duke Comprehensive Cancer Center, Durham, North Carolina 27710-0001, USA. crawf006@mc.duke.edu
D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000009:adverse effects / Q000627:therapeutic use*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000628:therapy*; D009503:Neutropenia / Q000139:chemically induced / Q000517:prevention & control; D011994:Recombinant Proteins; D018570:Risk Assessment
D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; C081222:sargramostim; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D000069585:Filgrastim